|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
93.44(B) |
Last
Volume: |
20,542,542 |
Avg
Vol: |
12,077,193 |
52
Week Range: |
$40.25 - $64.73 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$0 |
$672,994 |
$672,994 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
616,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$44,859,834 |
Total People Sold |
0 |
0 |
2 |
5 |
Total Sell Transactions |
0 |
0 |
2 |
11 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Caforio Giovanni |
Chief Executive Officer |
|
2016-03-06 |
4 |
D |
$64.71 |
$188,888 |
D/D |
(2,919) |
79,457 |
|
- |
|
Caforio Giovanni |
Chief Executive Officer |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,749 |
82,376 |
|
- |
|
Caforio Giovanni |
Chief Executive Officer |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,889 |
79,627 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2016-03-06 |
4 |
D |
$64.71 |
$35,332 |
D/D |
(546) |
50,964 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
689 |
51,510 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
724 |
50,821 |
|
- |
|
Gordon Murdo |
SVP, Head of Worldwide Markets |
|
2016-03-06 |
4 |
D |
$64.71 |
$72,799 |
D/D |
(1,125) |
2,706 |
|
- |
|
Gordon Murdo |
SVP, Head of Worldwide Markets |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,220 |
3,831 |
|
- |
|
Gordon Murdo |
SVP, Head of Worldwide Markets |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,282 |
2,611 |
|
- |
|
Caldarella Joseph C |
SVP & Controller |
|
2016-03-06 |
4 |
D |
$64.71 |
$100,559 |
D/D |
(1,554) |
48,536 |
|
- |
|
Caldarella Joseph C |
SVP & Controller |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,837 |
50,090 |
|
- |
|
Caldarella Joseph C |
SVP & Controller |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,931 |
48,253 |
|
- |
|
Caldarella Joseph C |
SVP & Controller |
|
2016-03-04 |
4 |
S |
$64.64 |
$837,916 |
D/D |
(12,962) |
46,322 |
|
- |
|
Caforio Giovanni |
Chief Executive Officer |
|
2016-02-17 |
4 |
S |
$63.58 |
$765,527 |
D/D |
(12,040) |
76,738 |
|
- |
|
Caforio Giovanni |
Chief Executive Officer |
|
2016-02-17 |
4 |
OE |
$22.89 |
$460,661 |
D/D |
20,125 |
88,778 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2016-02-17 |
4 |
S |
$63.57 |
$645,342 |
D/D |
(10,152) |
309,547 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2016-02-17 |
4 |
OE |
$22.73 |
$330,949 |
D/D |
14,560 |
319,699 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-02-12 |
4 |
AS |
$59.69 |
$692,649 |
D/D |
(11,600) |
392,854 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-02-11 |
4 |
AS |
$59.50 |
$690,374 |
D/D |
(11,600) |
404,454 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-02-04 |
4 |
D |
$59.70 |
$7,648,704 |
D/D |
(128,119) |
416,054 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
85,569 |
458,912 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
148,180 |
445,820 |
|
- |
|
Paliwal Dinesh C |
Director |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,257 |
3,257 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-01-05 |
4 |
AS |
$68.16 |
$791,028 |
D/D |
(11,600) |
310,424 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-01-04 |
4 |
AS |
$66.92 |
$776,332 |
D/D |
(11,600) |
322,024 |
|
- |
|
953 Records found
|
|
Page 30 of 39 |
|
|